Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...
Pursuing dangerous Medicaid block grant schemes and allowing flagrant violations of unequivocal state laws looks like ...
Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...
6h
Hosted on MSNWegovy and Ozempic stars dim amid overuse concernsThe luster is starting to wear off GLP-1 weight-loss drugs including Wegovy and Ozempic as more clinicians warn patients ...
Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...
The Trump administration has promised that addressing childhood obesity will be a key part of its “Make America Healthy Again ...
Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...
Groundbreaking research reveals how a popular diabetes and weight loss medication might offer unexpected help for those dealing with alcohol challenges.
The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results